Hla-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: a Multicentre Analysis

Highlights • HaploSCT is a valuable alternative for HL patients relapsing after an ASCT. • In this series, 2-year PFS and OS probabilities were 54% and 66%, respectively. • This appears to be a feasible strategy for patients in middle-income countries.

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017
Main Authors: Pitombeira de Lacerda, Marcelo, Arrais Rodrigues, Celso, Pereira, André Domingues, Novis, Yana, Fonseca, Marina, Silva, Roberto L, Macedo, Maria C.M.A, Hamerschlak, Nelson, Esteves, Iracema, Schmidt Filho, Jayr, Nascimento, Marina M, Rocha, Vanderson
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • HaploSCT is a valuable alternative for HL patients relapsing after an ASCT. • In this series, 2-year PFS and OS probabilities were 54% and 66%, respectively. • This appears to be a feasible strategy for patients in middle-income countries.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2017.01.079